pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,295 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1869Endpoints1449Fierce Biotech766BioSpace758BioPharma Dive548raps249onclive165fda recalls120
therapy area
allOncology12917Rare Disease3340Immunology3024Cardiology2858Hematology2298Pulmonology2255Vaccines
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 5h agoDealPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 5h agoDealPositive↗ source
← prev
page 1 of 52
next →
fda medwatch115
globenewswire health73
fda press62
1854
Psychiatry & CNS1230
Ophthalmology1134
Endocrinology & Metabolism807
Pain791
Nephrology785
  • Nine California biotech firms slash at least half of their workforces amid statewide cuts
    Workforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…
    BioSpace · 7h agoLayoffsNegative↗ source
  • Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raise
    Three biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…
    BioSpace · 7h agoDealNeutral↗ source
  • GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent deal
    GSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
    BioSpace · 23h agoApprovalPositive↗ source
  • Pfizer partners with China's Starna Therapeutics on up to $2.6B in vivo CAR-T deal for autoimmune diseases
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to develop in vivo CAR-T therapies targeting autoimmune diseases. The agreement covers three preclinical CAR-T programs, w…
    BioSpace · 22h agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination, raising uncertainty for agency’s future
    The White House pulled its nomination of Heidi Overton for FDA commissioner, a move that surprised members of the Senate health committee. Overton’s removal leaves the agency without a permanent h…
    STAT · 16h agoRegulatoryNegative↗ source
  • FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failure
    The U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • Merck halts development of BTK inhibitor nemtabrutinib after safety concerns
    Merck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…
    BioSpace · 21h agoRegulatoryNegative↗ source
  • FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drug
    The U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…
    STAT · 21h agoCRLNegative↗ source
  • FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concerns
    Summit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
    BioSpace · 23h agoRegulatoryNegative↗ source
  • Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater China
    Pfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
    Endpoints · 23h agoDealPositive↗ source
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 1d agoDealNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 1d agoDealNeutral↗ source
  • Trump administration withdraws Heidi Overton’s FDA nomination amid Senate support concerns
    The Trump administration has pulled the nomination of Heidi Overton to become the U.S. Food and Drug Administration commissioner, saying she lacked sufficient backing to win Senate confirmation. T…
    STAT · 21h agoRegulatoryNeutral↗ source
  • Debate Over Medical School Structure Emerges as U.S. Loses Measles Elimination Status
    A discussion is unfolding about whether the traditional four‑year medical school model should be broken into separate components. The idea was voiced by a medical student who asked if every part of…
    STAT · 23h agoNegative↗ source
  • STAT+: Influential preventive services panel to meet for first time in more than a year
    A task force, meeting after a long delay, will discuss coverage of treatments for cervical cancer, perinatal depression, and alcohol use.
    STAT · 15h agoRegulatoryNeutral↗ source
  • NIH to relocate its final research chimpanzees to sanctuary in Texas next year
    The National Institutes of Health announced that the last group of government‑owned chimpanzees still housed in a laboratory will be moved to a sanctuary early next year. The animals, about three d…
    STAT · 15h agoPositive↗ source
  • Isomorphic Labs raises record $5 billion in Series C, doubling its May funding
    Isomorphic Labs, an AI-driven drug design company, announced a $5 billion Series C financing, the largest private biotech raise ever and more than double its $2.1 billion Series B from May. The ro…
    BioSpace · 1d agoDealPositive↗ source
  • Sellas cancer vaccine cuts death risk by 41% in late-stage AML trial
    Sellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 2d agoApprovalPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 1d agoApprovalPositive↗ source
  • FDA approves Roche's new breast cancer drug, poised to become its top-selling product
    The U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…
    STAT · 1d agoApprovalPositive↗ source
  • Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trial
    Sellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
    STAT · 2d agoPositive readoutPositive↗ source
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 1d agoPositive readoutPositive↗ source